JP Morgan Initiates Coverage On RayzeBio with Overweight Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has initiated coverage on RayzeBio (NASDAQ:RYZB) with an Overweight rating and a price target of $30.
October 10, 2023 | 9:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan has initiated coverage on RayzeBio with an Overweight rating and a price target of $30, which could positively impact the stock's performance.
The initiation of coverage by JP Morgan, a major financial institution, with an Overweight rating indicates a positive outlook for RayzeBio. The price target of $30 also suggests that the analyst believes the stock is undervalued, which could lead to an increase in the stock's price as the market adjusts to this new information.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100